HF3054 (Legislative Session 94 (2025-2026))
Prescription drug transparency provisions modified.
Related bill: SF3294
AI Generated Summary
Purpose of the Bill
The bill seeks to enhance transparency in prescription drug pricing and spending within the state of Minnesota. It includes modifications to existing transparency requirements, particularly for entities participating in the federal 340B Drug Pricing Program, and establishes new reporting obligations for drug manufacturers when prices increase.
Main Provisions
340B Program Reporting: Requires covered entities in the 340B Drug Pricing Program to report specific data about drug acquisition costs, payments received, and related expenses to the state commissioner annually. Hospitals must also report detailed drug-level data.
Enforcement and Exceptions: Imposes fines on covered entities failing to report data as required and allows for possible exemptions or extensions.
Annual Legislative Reports: Mandates the commissioner to submit an annual report to the state legislature on aggregated data from 340B covered entities.
Prescription Drug Price Transparency: Sets requirements for drug manufacturers to submit detailed reports on price increases of certain drugs, particularly significant ones, including the reasons for the increase, sales data, and the manufacturer's costs and profits.
Public Posting of Drug Pricing Information: Obligates the commissioner to make certain drug pricing information available to the public through a website, while ensuring trade secrets and non-public data remain confidential.
Monitoring of Drugs of Public Interest: Directs the commissioner to identify and list drugs that are of significant public interest due to pricing concerns, with a quarterly process to review and list these drugs for potential requests of additional data.
Significant Changes to Existing Law
- Expands upon existing statutory requirements for 340B entities and drug manufacturers by detailing more comprehensive data to be reported.
- Introduces penalties for non-compliance with data reporting standards.
- Enlarges the scope of drugs included in periodic reviews and public interest listings based on reported price changes and public comments.
Relevant Terms
340B program, drug price transparency, MinnesotaCare, Medicare, commercial insurance, prescription drug price increase, drug manufacturer reporting, drug pricing, pricing unit, pharmacy benefit manager (PBM), wholesale drug distributor, public interest drugs, FDA-approved.
Bill text versions
- Introduction PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| April 01, 2025 | House | Floor | Action | Introduction and first reading, referred to | Health Finance and Policy |
Citations
[
{
"analysis": {
"added": [],
"removed": [],
"summary": "This bill modifies data classification related to nonpublic data submissions under section 62J.461.",
"modified": [
"Clarification on the classification of data provided by covered entities under 62J.461."
]
},
"citation": "13.02",
"subdivision": "subdivision 9"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "This section covers contested case procedures relevant to entities that do not comply with reporting requirements under section 62J.461.",
"modified": [
"Referenced for judicial review of fines levied under section 62J.461."
]
},
"citation": "14.57",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Judicial review provisions under chapter 14 are extended to fines for non-compliance under section 62J.461.",
"modified": [
"Applies contested case and judicial review provisions to penalties imposed under section 62J.461."
]
},
"citation": "14.69",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Related standards for private entity contracting referenced for public posting of drug price information.",
"modified": [
"Private entities must meet certain standards for handling data related to drug pricing."
]
},
"citation": "62U.04",
"subdivision": "subdivision 6"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Addresses trade secret protection related to information under section 62J.84.",
"modified": [
"Clarifies conditions under which information is withheld from public disclosure."
]
},
"citation": "13.37",
"subdivision": "subdivision 1",
"subdivision_detail": "paragraph b"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Relates to the Defend Trade Secrets Act, mentioned in context of data protection.",
"modified": [
"Provides federal basis for protecting trade secrets submitted under section 62J.84."
]
},
"citation": "18 U.S.C. 1836",
"subdivision": ""
}
]